SAB Biotherapeutics Inc
SABS3.180USD
-0.070-2.15%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
29.55MMarket Cap
LossP/E TTM
More Details of SAB Biotherapeutics Inc Company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
SAB Biotherapeutics Inc Info
Ticker SymbolSABS
Company nameSAB Biotherapeutics Inc
IPO dateJan 12, 2021
CEOMr. Samuel J. Reich
Number of employees63
Security typeOrdinary Share
Fiscal year-endJan 12
Address777 W 41St St
CityMIAMI BEACH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33140
Phone13058452813
Websitehttps://www.sab.bio/
Ticker SymbolSABS
IPO dateJan 12, 2021
CEOMr. Samuel J. Reich
Company Executives of SAB Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
29.34K
-6.31%
Mr. David Link
Mr. David Link
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Dr. William J. Polvino, M.D.
Dr. William J. Polvino, M.D.
Independent Director
Independent Director
--
--
Ms. Katie Katherine Ellias
Ms. Katie Katherine Ellias
Independent Director
Independent Director
--
--
Dr. Eddie J. Sullivan, Ph.D.
Dr. Eddie J. Sullivan, Ph.D.
President, Director
President, Director
--
--
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
29.34K
-6.31%
Mr. David Link
Mr. David Link
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Nov 3
Updated: Mon, Nov 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Commodore Capital LP
42.28%
Vivo Opportunity Fund Holdings, L.P.
42.28%
Sessa Capital
21.12%
BVF Partners L.P.
8.82%
Sullivan (Eddie Joe)
5.03%
Shareholders
Shareholders
Proportion
Commodore Capital LP
42.28%
Vivo Opportunity Fund Holdings, L.P.
42.28%
Sessa Capital
21.12%
BVF Partners L.P.
8.82%
Sullivan (Eddie Joe)
5.03%
Shareholder Types
Shareholders
Proportion
Hedge Fund
72.49%
Other Insider Investor
42.28%
Individual Investor
13.75%
Investment Advisor/Hedge Fund
4.18%
Investment Advisor
3.23%
Corporation
0.53%
Family Office
0.49%
Bank and Trust
0.18%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
63
8.34M
80.08%
+4.93M
2025Q2
77
3.86M
41.43%
-1.53M
2025Q1
83
4.42M
47.57%
-1.24M
2024Q4
84
4.36M
47.19%
-1.19M
2024Q3
92
4.88M
52.85%
-650.39K
2024Q2
94
4.85M
52.54%
-723.93K
2024Q1
99
5.12M
55.54%
-327.29K
2023Q4
101
5.29M
57.38%
+3.28M
2023Q3
126
1.82M
35.87%
-989.33K
2023Q2
130
1.88M
37.39%
-929.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Commodore Capital LP
4.40M
42.28%
+4.40M
--
Sep 26, 2025
Sessa Capital
2.20M
21.12%
+1.74M
+379.53%
Sep 29, 2025
BVF Partners L.P.
917.83K
8.82%
--
--
Jun 30, 2025
Sullivan (Eddie Joe)
523.23K
5.03%
--
--
Aug 01, 2025
Hamilton (Christine E)
501.81K
4.82%
--
--
Aug 01, 2025
Hamilton (Edward D.)
308.32K
2.96%
--
--
Aug 01, 2025
The Vanguard Group, Inc.
282.37K
2.71%
+4.86K
+1.75%
Jun 30, 2025
Geode Capital Management, L.L.C.
84.77K
0.81%
+87.00
+0.10%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Date
Type
Ratio
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
